Get the Stockscreener App
4.575
0.66%
0.015
Foghorn Therapeutics Inc stock is traded at $4.575, with a volume of 112.33K.
It is up +0.66% in the last 24 hours and up +12.78% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.56
Open:
$4.6
24h Volume:
112.33K
Relative Volume:
0.58
Market Cap:
$259.29M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.9551
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
-8.57%
1M Performance:
+12.78%
6M Performance:
+10.87%
1Y Performance:
-41.90%
1-Day Range:
$4.40
$4.63
1-Week Range:
$4.40
$5.255
52-Week Range:
$2.9448
$8.445
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.585 | 257.87M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.22 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.91 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.37 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Foghorn Therapeutics (Nasdaq: FHTX) to Join 8th Evercore Healthcare Conference - Stock Titan
Why Foghorn Therapeutics Inc. stock is a must watch in 2025Quarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Can Foghorn Therapeutics Inc. stock maintain growth trajectory2025 Performance Recap & Risk Controlled Daily Plans - newser.com
How Foghorn Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Market Pulse Alerts - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock bottoming outShare Buyback & Fast Gain Stock Tips - newser.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? - Zacks Investment Research
FHTX: SMARCA2 program advances with Lilly partnership; multiple novel assets near IND and strong funding - TradingView
Identifying reversal signals in Foghorn Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - newser.com
How Foghorn Therapeutics Inc. stock compares to growth peers2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Check Out Foghorn Therapeutics Inc (FHTX)’s Trade Data Rather Than the Analysts’ Views - Setenews
4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewswire Inc.
Applying big data sentiment scoring on Foghorn Therapeutics Inc.Trade Ideas & Real-Time Chart Breakout Alerts - newser.com
Why Foghorn Therapeutics Inc. stock could outperform in 2025July 2025 Weekly Recap & Capital Efficiency Focused Ideas - newser.com
How risky is Foghorn Therapeutics Inc. stock now2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Published on: 2025-11-15 18:34:42 - newser.com
Volatility clustering patterns for Foghorn Therapeutics Inc.July 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - newser.com
Will Foghorn Therapeutics Inc. stock maintain growth story2025 Technical Overview & Weekly Consistent Profit Watchlists - Fundação Cultural do Pará
Foghorn Therapeutics Unveils Strategic Advancements with Lilly - MSN
Momentum divergence signals in Foghorn Therapeutics Inc. chartJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):